News | Atrial Fibrillation | December 18, 2018

Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award

Implantable device isolates source of AFib and filters blood clots to reduce stroke risk

Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award

December 18, 2018 — Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the International Conference for Innovations in Cardiovascular Systems (ICI), Dec. 2-4 in Tel Aviv, Israel. AuriGen Medical, which specializes in the treatment of atrial fibrillation, is developing the first heart implant to treat both the stroke and heart failure risk associated with this often fatal condition.The Global Innovation award attracted entries from the best medical device and pharmaceutical start-ups from around the world.

Everyday over 30 million patients suffer with atrial fibrillation, an irregular heartbeat which can lead to stroke, dementia, heart failure and death. Unfortunately for the majority of atrial fibrillation patients with persistent longstanding disease, the current treatment options are routinely ineffective, which results in billions in direct healthcare costs.

The AuriGen Device incorporates patented sensor and implant technology. This technology is designed to quickly and safely isolate the source of atrial fibrillation and filter blood clots, preventing them from transferring to the brain, thereby reducing the risk of stroke.

AuriGen Medical recently ranked first out of almost 1,300 EU Horizon 2020 funding applications. The technology has secured a €2.5 million cash injection from the European Union's €80 billion research and innovation program.

For more information: www.aurigenmedical.com

Related Content

Frequent Drinking Greater Risk Factor for Heart Rhythm Disorder Than Binge Drinking

Image courtesy of the American Heart Association.

News | Atrial Fibrillation | October 22, 2019
October 22, 2019 —  Drinking small amounts of alcohol frequently is linked with a higher likelihood of...
Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Feature | Atrial Fibrillation | July 24, 2019
July 24, 2019 — Atrial fibrillation (AFib) is a common abnormal heart rhythm.
New Technology Improves Atrial Fibrillation Detection After Stroke
News | Atrial Fibrillation | July 19, 2019
A new method of evaluating irregular heartbeats outperformed the approach that’s currently used widely in stroke units...
An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Overlay Init